Abstract 461P
Background
Meta-analyses and cohort studies have shown blood trace mineral concentration may be associated with incidence risk of lung cancer. However, there is no comprehensive study to investigate causal relationship between blood trace mineral and lung cancer. The purpose of this study is to inspect the causal effect of blood trace mineral concentration on lung cancer with Mendelian randomization (MR) method.
Methods
With a two‐sample MR approach, we analyzed the summary data of zinc, selenium, copper from the Queensland Institute of Medical Research(QIMR, 2603 individuals) and The Avon Longitudinal Study of Parents and Children (ALSPAC, 10115 individuals), data of calcium from discovery cohorts(39400 individuals) and replication cohorts(21875 individuals), data of iron from Genetics of Iron Status Consortium(23986 individuals), data of lung cancer patients from Consortium and International Lung Cancer Consortium (ILCCO, 11 348 lung cancer cases and 15 861 controls) to assess the possible causal relationship of blood trace mineral concentration on the risk of lung cancer.
Results
Our results indicated that genetically predicted higher blood copper level has a positive association with lung cancer, each per-unit increase in copper is associated with a 14% increase in the risk of lung cancer (odds ratio [OR]: 1.14, 95% CI = 1.01‐1.29; P = 0.04). Additionally, blood calcium, zinc, selenium, iron were not causal factors for lung cancer.
Conclusions
Genetically higher blood copper is positively associated with risk of lung cancer, and more work is needed to examine the potential mechanism.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Key R&D Program of China (Grant No. 2016YFC0905500, 2016YFC0905503); Science and Technology Program of Guangdong (Grant No. 2017B020227001, 2016A020215084); Science and Technology Program of Guangzhou (Grant No. 201607020031, 201400000001-2); Chinese National Natural Science Foundation project (Grant No. 81772476, 81572659,81602011); Pearl River Nova Program of Guangzhou (Grant No. 201610010048); National Natural Science Funds for Young Scholars of China (Grant No. 81502355).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
258P - Assessment of sexual health in patients treated for ovarian cancer
Presenter: Renu Madan
Session: Poster display session
Resources:
Abstract
259P - The BOT patients fail to benefit from surgical staging procedures in prognosis and fertility outcomes: A retrospective analysis
Presenter: Li Na
Session: Poster display session
Resources:
Abstract
260P - Malignant ovarian germ cell tumours (MOGCT): Treatment results of 149 pts
Presenter: Dzhennet Chekini
Session: Poster display session
Resources:
Abstract
261P - Ovarian germ cell tumours - challenges and outcomes from a tertiary care centre in South India
Presenter: Vishnu Sreedath
Session: Poster display session
Resources:
Abstract
262P - Gestational trophoblastic tumours: Experience of the medical oncology department Hassan II University Hospital-Morocco about 29 cases
Presenter: Karima Oualla
Session: Poster display session
Resources:
Abstract
263TiP - ATHENA (GOG-3020/ENGOT-ov45): A randomised, double-blind, placebo-controlled phase III study of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib + the PD-1 inhibitor nivolumab following frontline platinum-based chemotherapy in ovarian cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
264TiP - ENGOT-ov43/KEYLYNK-001: A phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA¬-nonmutated advanced epithelial ovarian cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
265TiP - KEYNOTE-826: A phase III randomized study of chemotherapy with or without pembrolizumab for first-line treatment of persistent, recurrent, or metastatic cervical cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
271P - Comparison between CHOP like regimens and DAEPOCH with or without Rituximab in adult high grade B cell lymphoma NOS; A retrospective study from a tertiary cancer hospital in South India
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
272P - Melatonin increases the chemosensitivity of diffuse large Bell lymphoma cells to Epirubicin by inhibiting P-glycoprotein expression via the NF-κB pathway
Presenter: Xiuhua Sun
Session: Poster display session
Resources:
Abstract